SCYNEXIS, Inc. Operating Cash Flow
SCYNEXIS, Inc. (SCYX) reported Operating Cash Flow of -$22.99 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-10
- SCYNEXIS, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$14.88M.
- SCYNEXIS, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$8.10M.
- SCYNEXIS, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $18.40M.
- SCYNEXIS, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$8.72M, a 1240.39% decline year-over-year.
- SCYNEXIS, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$5.28M.
- SCYNEXIS, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$24.01M, a 139.91% decline from fiscal 2023.
- SCYNEXIS, Inc. net cash provided by (used in) operating activities for fiscal 2023 was $60.16M.
- SCYNEXIS, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$79.88M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$14.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$22.99M 10-Q · filed 2026-08-10 | -$4.58M derived: sum of 3 quarters · filed 2026-08-10 | -$13.31M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$8.10M 10-Q · filed 2026-05-11 | $10.30M derived: sum of 2 quarters · filed 2026-05-11 | $1.58M derived: sum of 3 quarters · filed 2026-05-11 | -$5.92M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $18.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $9.68M derived: sum of 2 quarters · filed 2026-03-04 | $2.18M derived: sum of 3 quarters · filed 2026-08-10 | -$5.28M 10-K · filed 2026-03-04 |
| 2025-09-30 | -$8.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$16.22M derived: sum of 2 quarters · filed 2026-08-10 | -$23.68M 10-Q · filed 2025-11-05 | -$33.59M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$7.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$14.96M 10-Q · filed 2026-08-10 | -$24.87M derived: sum of 3 quarters · filed 2026-08-10 | -$24.10M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$7.46M 10-Q · filed 2026-05-11 | -$17.37M derived: sum of 2 quarters · filed 2026-05-11 | -$16.61M derived: sum of 3 quarters · filed 2026-05-11 | -$27.47M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$9.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$9.14M derived: sum of 2 quarters · filed 2026-03-04 | -$20.00M derived: sum of 3 quarters · filed 2026-03-04 | -$24.01M 10-K · filed 2026-03-04 |
| 2024-09-30 | $765.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$10.10M derived: sum of 2 quarters · filed 2025-11-05 | -$14.10M 10-Q · filed 2025-11-05 | -$21.84M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$10.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$14.87M 10-Q · filed 2025-08-13 | -$22.60M derived: sum of 3 quarters · filed 2025-08-13 | -$10.18M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$4.01M 10-Q · filed 2025-05-15 | -$11.74M derived: sum of 2 quarters · filed 2025-05-15 | $677.00K derived: sum of 3 quarters · filed 2025-05-15 | $75.08M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$7.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $4.68M derived: sum of 2 quarters · filed 2025-03-12 | $79.08M derived: sum of 3 quarters · filed 2025-03-12 | $60.16M 10-K · filed 2025-03-12 |
| 2023-09-30 | $12.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $86.82M derived: sum of 2 quarters · filed 2024-11-06 | $67.89M 10-Q · filed 2024-11-06 | $45.09M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $74.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $55.48M 10-Q · filed 2024-08-08 | $32.67M derived: sum of 3 quarters · filed 2024-08-08 | $10.16M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$18.92M 10-Q · filed 2024-05-08 | -$41.73M derived: sum of 2 quarters · filed 2024-05-08 | -$64.24M derived: sum of 3 quarters · filed 2024-05-08 | -$82.82M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$22.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$45.31M derived: sum of 2 quarters · filed 2024-03-28 | -$63.90M derived: sum of 3 quarters · filed 2024-03-28 | -$79.88M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$22.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$41.09M derived: sum of 2 quarters · filed 2023-11-13 | -$57.08M 10-Q · filed 2023-11-13 | -$82.60M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$18.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$34.57M 10-Q · filed 2023-08-14 | -$60.09M derived: sum of 3 quarters · filed 2023-08-14 | -$76.67M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$15.99M 10-Q · filed 2023-05-10 | -$41.51M derived: sum of 2 quarters · filed 2023-05-10 | -$58.09M derived: sum of 3 quarters · filed 2023-05-10 | -$69.79M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$25.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$42.11M derived: sum of 2 quarters · filed 2023-03-31 | -$53.80M derived: sum of 3 quarters · filed 2023-03-31 | -$54.56M 10-K · filed 2023-03-31 |
| 2021-09-30 | -$16.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$28.28M derived: sum of 2 quarters · filed 2022-11-09 | -$29.04M 10-Q · filed 2022-11-09 | -$45.61M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$11.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$12.45M 10-Q · filed 2022-08-15 | -$29.03M derived: sum of 3 quarters · filed 2022-08-15 | -$38.90M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$759.00K 10-Q · filed 2022-05-12 | -$17.33M derived: sum of 2 quarters · filed 2022-05-12 | -$27.20M derived: sum of 3 quarters · filed 2022-05-12 | -$36.06M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$16.57M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | -$26.44M derived: sum of 2 quarters · filed 2022-03-29 | -$35.30M derived: sum of 3 quarters · filed 2022-03-29 | -$49.35M 10-K · filed 2022-03-29 |
| 2020-09-30 | -$9.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$18.73M derived: sum of 2 quarters · filed 2021-11-10 | -$32.78M 10-Q · filed 2021-11-10 | -$46.24M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$8.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$22.91M 10-Q · filed 2021-08-16 | -$36.37M derived: sum of 3 quarters · filed 2021-08-16 | -$46.77M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | -$14.06M 10-Q · filed 2021-05-17 | -$27.52M derived: sum of 2 quarters · filed 2021-05-17 | -$37.92M derived: sum of 3 quarters · filed 2021-05-17 | -$45.67M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | -$13.46M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | -$23.86M derived: sum of 2 quarters · filed 2021-03-29 | -$31.62M derived: sum of 3 quarters · filed 2021-03-29 | -$38.12M 10-K · filed 2021-03-29 |
| 2019-09-30 | -$10.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$18.16M derived: sum of 2 quarters · filed 2020-11-06 | -$24.66M 10-Q · filed 2020-11-06 | -$30.72M derived: sum of 4 quarters · filed 2020-11-06 |
| 2019-06-30 | -$7.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$14.26M 10-Q · filed 2020-08-10 | -$20.32M derived: sum of 3 quarters · filed 2020-08-10 | -$26.46M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | -$6.50M 10-Q · filed 2020-05-11 | -$12.56M derived: sum of 2 quarters · filed 2020-05-11 | -$18.71M derived: sum of 3 quarters · filed 2020-05-11 | -$26.61M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | -$6.06M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | -$12.21M derived: sum of 2 quarters · filed 2020-03-11 | -$20.10M derived: sum of 3 quarters · filed 2020-03-11 | -$28.32M 10-K · filed 2020-03-11 |
| 2018-09-30 | -$6.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$14.05M derived: sum of 2 quarters · filed 2019-11-12 | -$22.27M 10-Q · filed 2019-11-12 | -$27.42M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | -$7.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$16.12M 10-Q · filed 2019-08-07 | -$21.27M derived: sum of 3 quarters · filed 2019-08-07 | -$26.52M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | -$8.22M 10-Q · filed 2019-05-08 | -$13.38M derived: sum of 2 quarters · filed 2019-05-08 | -$18.62M derived: sum of 3 quarters · filed 2019-05-08 | -$26.00M derived: sum of 4 quarters · filed 2019-05-08 |
| 2017-12-31 | -$5.16M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | -$10.40M derived: sum of 2 quarters · filed 2019-03-14 | -$17.78M derived: sum of 3 quarters · filed 2019-03-14 | -$24.56M 10-K · filed 2019-03-14 |
| 2017-09-30 | -$5.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$12.63M derived: sum of 2 quarters · filed 2018-11-13 | -$19.40M 10-Q · filed 2018-11-13 | -$23.95M derived: sum of 4 quarters · filed 2018-11-13 |
| 2017-06-30 | -$7.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$14.15M 10-Q · filed 2018-08-09 | -$18.71M derived: sum of 3 quarters · filed 2018-08-09 | -$25.55M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | -$6.77M 10-Q · filed 2018-05-08 | -$11.33M derived: sum of 2 quarters · filed 2018-05-08 | -$18.17M derived: sum of 3 quarters · filed 2018-05-08 | -$27.16M derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | -$4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | -$11.40M derived: sum of 2 quarters · filed 2018-03-13 | -$20.39M derived: sum of 3 quarters · filed 2018-03-13 | -$29.35M 10-K · filed 2018-03-13 |
| 2016-09-30 | -$6.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$15.84M derived: sum of 2 quarters · filed 2017-11-07 | -$24.80M 10-Q · filed 2017-11-07 | -$30.78M derived: sum of 4 quarters · filed 2017-11-07 |
| 2016-06-30 | -$8.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$17.95M 10-Q · filed 2017-08-08 | -$23.93M derived: sum of 3 quarters · filed 2017-08-08 | -$29.68M derived: sum of 4 quarters · filed 2017-08-08 |
| 2016-03-31 | -$8.96M 10-Q · filed 2017-05-08 | -$14.94M derived: sum of 2 quarters · filed 2017-05-08 | -$20.69M derived: sum of 3 quarters · filed 2017-05-08 | -$28.96M derived: sum of 4 quarters · filed 2017-05-08 |
| 2015-12-31 | -$5.98M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | -$11.73M derived: sum of 2 quarters · filed 2017-03-13 | -$20.00M derived: sum of 3 quarters · filed 2017-03-13 | -$24.55M 10-K · filed 2017-03-13 |
| 2015-09-30 | -$5.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | -$14.02M derived: sum of 2 quarters · filed 2016-11-07 | -$18.56M 10-Q · filed 2016-11-07 | -$20.28M derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-06-30 | -$8.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | -$12.82M 10-Q · filed 2016-08-08 | -$14.54M derived: sum of 3 quarters · filed 2017-03-13 | |
| 2015-03-31 | -$4.55M 10-Q · filed 2016-05-09 | -$6.27M derived: sum of 2 quarters · filed 2017-03-13 | ||
| 2014-12-31 | -$1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | -$9.47M 10-K · filed 2017-03-13 | ||
| 2014-09-30 | -$7.75M 10-Q · filed 2015-11-13 | |||
| 2014-03-31 | $161.00K 10-Q/A · filed 2014-07-11 | |||
| 2013-03-31 | -$1.85M 10-Q/A · filed 2014-07-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |